856850-18-5 Usage
General Description
2-(bromomethyl)-4-chloropyridine is a chemical compound with the molecular formula C6H5BrClN. It is a halogenated pyridine derivative that is commonly used as a building block in organic synthesis. 2-(bromomethyl)-4-chloropyridine is a pale yellow to yellowish-brown liquid at room temperature and is soluble in polar solvents such as ethanol and dimethyl sulfoxide. 2-(bromomethyl)-4-chloropyridine is a versatile intermediate in the pharmaceutical and agrochemical industries, and it is often used in the preparation of various biologically active compounds and pesticides. It is important to handle this chemical with caution, as it is flammable and can cause skin and eye irritation upon contact.
Check Digit Verification of cas no
The CAS Registry Mumber 856850-18-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,5,6,8,5 and 0 respectively; the second part has 2 digits, 1 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 856850-18:
(8*8)+(7*5)+(6*6)+(5*8)+(4*5)+(3*0)+(2*1)+(1*8)=205
205 % 10 = 5
So 856850-18-5 is a valid CAS Registry Number.
856850-18-5Relevant articles and documents
Rational Design of 2-Chloroadenine Derivatives as Highly Selective Phosphodiesterase 8A Inhibitors
Huang, Yadan,Wu, Xu-Nian,Zhou, Qian,Wu, Yinuo,Zheng, Dongxiao,Li, Zhe,Guo, Lei,Luo, Hai-Bin
, p. 15852 - 15863 (2020/12/23)
To validate the hypothesis that Tyr748 is a crucial residue to aid the discovery of highly selective phosphodiesterase 8A (PDE8A) inhibitors, we identified a series of 2-chloroadenine derivatives based on the hit clofarabine. Structure-based design targeting Tyr748 in PDE8 resulted in the lead compound 3a (IC50 = 0.010 μM) with high selectivity with a reasonable druglike profile. In the X-ray crystal structure, 3a bound to PDE8A with a different mode from 3-isobutyl-1-methylxanthine (a pan-PDE inhibitor) and gave a H-bond of 2.7 ? with Tyr748, which possibly interprets the 220-fold selectivity of 3a against PDE2A. Additionally, oral administration of compound 3a achieved remarkable therapeutic effects against vascular dementia (VaD), indicating that PDE8 inhibitors could serve as potential anti-VaD agents.
